The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth Market
Dallas, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc.(NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product ('GROW') and erectile dysfunction (ED) drug ('Mango'), is excited to announce the highly anticipated release and availability of 'PRIME' by MangoRx, Powered by Kyzatrex ("PRIME") bringing the FDA-approved oral testosterone replacement therapy (TRT) treatment to consumers...
Login or create a forever free account to read this news
Sign up/Log in